A proprietary portfolio
of peptide derivatives

Preclinical and clinical trials

1. Preclinical:

preclinical tests have been performed with promising results.

Since 2020, two compounds, both peptide derivatives of the TAFA4 protein, have principally been used, with administration via several routes — notably the intravenous, subcutaneous, intrathecal and oral routes — opening up new possibilities for responding to the needs of a great diversity of different medical situations and paving the way for global adoption.

During the preclinical phase, Tafalgie Therapeutics demonstrated that TAFA4 and its peptide derivatives:

• Effectively modulate the propagation of pain after injury, even for pain of moderate to severe intensity,
• Without the side effects currently associated with most painkillers,
• Remain effective even after repeated administration (no development of tolerance phenomena),
• Remain effective even after oral administration, an exceptional advantage for a peptide.

2. Clinical:

2025 has seen the entry of Tafalgie into the arena of clinical trials in humans. This is a key step in the history of the company and its development.

Tafalgie Therapeutics began its first clinical trial with TT5 in 2025. The clinical development plan is as follows:

Underway

Performance of a phase I clinical trial (dose-escalation trial with a single dose and then repeated doses) in healthy volunteers.

To come

We will immediately move on to a phase Ib trial, to obtain additional toxicity/safety data and preliminary data for efficacy in patients undergoing surgery.

To come

Launch of phase IIa studies to evaluate the efficacy of TT5 for the selected indications. The Tafalgie team and the clinical advisory board are currently selecting the target indications , including those in the domain of rare diseases….

Other clinical trials will follow on second- and third-generation candidate drugs.

A process for the selection, optimization and production of a second and third candidate drug is underway. These compounds will become polyvalent oral drugs with optimized production costs and stability.

3. Veterinary Market: Proof of translational efficacy

The TAFADOG study is an early-stage trial to obtain proof-of-efficacy performed by an independent academic partner in a real clinical context, with privately owned female dogs undergoing ovariectomy (sterilization).

Intellectual property

We have five families of patents (all filed):

• 1 family of patents under exclusive license,
• 2 families of patents fully owned by Tafalgie Therapeutics,
• 2 other families of patients jointly owned with AMU and the CNRS for which acquisition is underway.

With protection by patents in more than 100 countries, our intellectual property portfolio is well-positioned to support the worldwide commercialization of our compounds.